MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new
MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new radiopharmaceutical, 123I-BMIPP (123I-beta-methyl-iodophenylpentadecanoic acid), for detection of cardiac ischemia in the emergency department. The cardiac imaging pharmaceutical will be manufactured at MDS Nordion's cyclotron facility in Vancouver, BC.
MRI Study Identifies Pelvic Floor Parameters that May Lead to Postpartum Stress Urinary Incontinence
October 2nd 2023Researchers found that the combination of a retrovesicourethral angle, functional urethral length, and bladder funnel on MRI exams in primiparous women had a 94.7 percent AUC for predicting postpartum stress urinary incontinence (SUI).
CAD Versus AI: Let Me Know When the Alphabet Soup Matters in Radiology
October 2nd 2023Is the continued rise of artificial intelligence (AI) driven by legitimate “machine learning,” or do the frequently “suspicious” chest X-rays and questionable detection of subtle findings on head CTs reveal a hype-driven train of new products with an ultimately “planned obsolescence”?
2 Clarke Drive
Cranbury, NJ 08512